Bylvay eases itching in episodic PFIC1, boosting daily life: Study
Bylvay (odevixibat) eased pruritus — itching — during episodes of progressive familial intrahepatic cholestasis (PFIC) type 1 caused by mutations in both copies of…
Bylvay (odevixibat) eased pruritus — itching — during episodes of progressive familial intrahepatic cholestasis (PFIC) type 1 caused by mutations in both copies of…
Throughout July, the nonprofit Biliary Atresia Research & Education (BARE) is holding its Live and Let Live(r) fundraising campaign to raise money and awareness…
BiTS, an antibody co-developed by researchers at New York University (NYU) to tame overactive immune T-cells, reduced inflammation and liver damage in a study that…
An imbalance in the blood between long-chain and very long-chain ceramides — fatty molecules that help fine-tune the body’s inflammatory response — may help indicate…
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
Researchers have developed a database of all ABCB11 mutations known to cause progressive familial intrahepatic cholestasis type 2 (PFIC2) and a new mouse model…
A targeted treatment called transarterial chemoembolization (TACE) successfully helped control hepatocellular carcinoma (HCC), the most common type of liver cancer, in a young woman with…
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…